Patients with cancer are at increased risk of infection due to a number of factors related to both their underlying malignancy and the treatment provided, most commonly from the administration of chemotherapeutic drugs.
This text, from an international team of experts, reviews the epidemiology, assessment and treatment of febrile neutropenia in a number of clinical settings.